131 related articles for article (PubMed ID: 37278044)
1. Naloxone Effects Against Cutaneous Leishmaniasis Caused by
Azizi H; Mahdavinik E; Hataminejad M; Khamesipour A; Montazeri S
Infect Disord Drug Targets; 2023; 23(6):e020623217598. PubMed ID: 37278044
[TBL] [Abstract][Full Text] [Related]
2. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Moosavian SA; Fallah M; Jaafari MR
Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
[TBL] [Abstract][Full Text] [Related]
3. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic effect of larval saliva and hemolymph of Lucilia sericata on the treatment of Leishmania major lesion in BALB/c mice946.
Rahimi S; Rafinejad J; Akhavan AA; Ahmadkhaniha R; Bakhtiyari M; Khamesipour A; Akbarzadeh K
Parasit Vectors; 2023 Feb; 16(1):72. PubMed ID: 36797798
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of amiodarone in treatment of cutaneous leishmaniasis caused by Leishmania major.
Bemani E; Oryan A; Bahrami S
Exp Parasitol; 2019 Oct; 205():107747. PubMed ID: 31442454
[TBL] [Abstract][Full Text] [Related]
6. Leishmanicidal potentials of
Sharifi F; Sharififar F; Pournamdari M; Ansari M; Tavakoli Oliaee R; Bamorovat M; Khosravi A; Keyhani AR; Salarkia E; Mortazaeizdeh A; Dabiri S; Khamesipour A; Sharifi I
J Med Microbiol; 2021 Jun; 70(6):. PubMed ID: 34115583
[No Abstract] [Full Text] [Related]
7. Sugar-based colloidal nanocarriers for topical meglumine antimoniate application to cutaneous leishmaniasis treatment: Ex vivo cutaneous retention and in vivo evaluation.
Aragão Horoiwa T; Cortez M; Sauter IP; Migotto A; Bandeira CL; Cerize NNP; de Oliveira AM
Eur J Pharm Sci; 2020 Apr; 147():105295. PubMed ID: 32145429
[TBL] [Abstract][Full Text] [Related]
8. Leishmania RNA virus 2 (LRV2) exacerbates dermal lesions caused by Leishmania major and comparatively unresponsive to meglumine antimoniate treatment.
Saberi R; Fakhar M; Hajjaran H; Abbaszadeh Afshar MJ; Mohebali M; Hezarjaribi HZ; Moghadam Y; Sharbatkhori M
Exp Parasitol; 2022 Oct; 241():108340. PubMed ID: 35932908
[TBL] [Abstract][Full Text] [Related]
9. Study of the
Azadi R; Alipour-Talesh G; Yazdanpanah MJ; Alavizadeh SH; Maleki M; Banihashemi M; Jaafari MR
J Vector Borne Dis; 2020; 57(1):78-84. PubMed ID: 33818460
[TBL] [Abstract][Full Text] [Related]
10. The combination therapy of meglumine antimoniate and oxiranes (epoxy-α-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis.
Gonçalves-Oliveira LF; Souza-Silva F; de Castro Côrtes LM; Veloso LB; Santini Pereira BA; Cysne-Finkelstein L; Lechuga GC; Bourguignon SC; Almeida-Souza F; da Silva Calabrese K; Ferreira VF; Alves CR
Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():101-108. PubMed ID: 31430693
[TBL] [Abstract][Full Text] [Related]
11. Stachys lavandulifolia Vahl. exhibits promising in vitro and in vivo antileishmanial activity against Leishmania major infection.
Alanazi AD; Albalawi AE; Almohammed HI; Shater AF
Trop Biomed; 2022 Sep; 39(3):412-420. PubMed ID: 36214438
[TBL] [Abstract][Full Text] [Related]
12. In vivo anti-leishmanial activity of concocted herbal topical preparation against Leishmania major (MRHO/IR/75/ER).
Saberi R; Zadeh AG; Afshar MJA; Fakhar M; Keighobadi M; Mohtasebi S; Rahimi-Esboei B
Ann Parasitol; 2021; 67(3):483-488. PubMed ID: 34953123
[TBL] [Abstract][Full Text] [Related]
13. Topical tamoxifen in the therapy of cutaneous leishmaniasis.
Trinconi CT; Reimão JQ; Bonano VI; Espada CR; Miguel DC; Yokoyama-Yasunaka JKU; Uliana SRB
Parasitology; 2018 Apr; 145(4):490-496. PubMed ID: 28274283
[TBL] [Abstract][Full Text] [Related]
14. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
[TBL] [Abstract][Full Text] [Related]
15. Naloxone Diminishes the Virulence and Modifies the Cellular Immune Responses of BALB/c Mice Infected with Leishmania major.
Alimohammadian MH; Riazi-Rad F; Asadi-Tat M; Darabi S; Darabi H; Khaze V; Bahrami F; Ajdary S
Acta Parasitol; 2021 Jun; 66(2):517-523. PubMed ID: 33211271
[TBL] [Abstract][Full Text] [Related]
16. Potential application of nanochitosan film as a therapeutic agent against cutaneous leishmaniasis caused by L. major.
Bahrami S; Esmaeilzadeh S; Zarei M; Ahmadi F
Parasitol Res; 2015 Dec; 114(12):4617-24. PubMed ID: 26346452
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo anti-parasitic activity of biogenic antimony sulfide nanoparticles on Leishmania major (MRHO/IR/75/ER).
Mohtasebi S; Mohebali M; Elikaee S; Akhoundi B; Foroushani AR; Teimouri A; Yarizadeh H
Parasitol Res; 2019 Sep; 118(9):2669-2678. PubMed ID: 31278518
[TBL] [Abstract][Full Text] [Related]
18. A natural cell-penetrating nanopeptide combined with pentavalent antimonial as experimental therapy against cutaneous leishmaniasis.
Valentim Silva JR; de Barros NB; Aragão Macedo SR; Ferreira ADS; Moreira Dill LS; Zanchi FB; do Nascimento JR; Fernandes do Nascimento FR; Lourenzoni MR; de Azevedo Calderon L; Soares AM; Nicolete R
Exp Parasitol; 2020 Oct; 217():107934. PubMed ID: 32698075
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis.
Fournet A; Ferreira ME; Rojas De Arias A; Torres De Ortiz S; Fuentes S; Nakayama H; Schinini A; Hocquemiller R
Antimicrob Agents Chemother; 1996 Nov; 40(11):2447-51. PubMed ID: 8913444
[TBL] [Abstract][Full Text] [Related]
20. A family cluster of cutaneous Leishmania major infection unresponsive to intralesional meglumine antimonial: Case reports.
Ziaee M; Ghatee MA; Taylor WR; Karamian M
Indian J Med Microbiol; 2022; 40(3):451-454. PubMed ID: 35680474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
